Arcutis Presents Late-Breaking Data From INTEGUMENT-PED

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...

Related Keywords

San Diego ,California ,United States ,American ,Amanda Sheldon ,Latha Vairavan ,Derek Cole ,Drug Administration ,Facebook ,Exchange Commission ,Nasdaq ,Head Of Corporate Communications ,Arcutis Biotherapeutics Inc ,American Academy Of Dermatology ,Eczema Area ,Severity Index ,Worst Itch Numeric Scale ,Investigator Global Assessment ,Atopic Dermatitis ,American Academy ,Prescription Drug User Fee Act ,Private Securities Litigation Reform Act ,Vice President ,Nasdaq Arqt ,Arcutis Biotherapeutics ,Nc ,Arqt ,Sad ,Roflumilast Cream ,